Follow @TheHPRA
Contact us
As Gaeilge
My HPRA:
Login
Register
About Us
Medicines
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Medicines
Safety Notices
My HPRA:
Login
Register
About Us
Medicines
COVID-19 vaccines and treatments
Our Role
Medicines Information
Safety Information
Safety Notices
Quality Information
Regulatory Information
News & Events
Special Topics
Emergency Medicines
Emergency Contact Details
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Product Information Update- Videx (Didanosine) and Zerit (Stavudine) capsules
Notice type:
3rd Party Publications
Date:
23/05/2016
New contraindication for concomitant use of didanosine with stavudine in the product information for Videx AND Zerit capsules.
Product name or type:
Videx 125 mg, 200 mg, 250 mg and 400mg Gastro-resistant hard capsules and Zerit 15 mg, 20 mg, 30 mg and 40mg hard capsules
Authorisation Number:
PA 0002/057/016-19 and EU/1/96/009/009
Authorisation Holder:
Bristol-Myers Squibb (BMS) Pharmaceuticals
Further Information:
Product Information Update- Videx (Didanosine) and Zerit (Stavudine) capsules
« Back
Date Printed: 11/05/2024